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Abstract
Background: The complexity of the mouse mu opioid receptor (Oprm) gene was demonstrated
by the identification of multiple alternatively spliced variants and promoters. Our previous studies
have identified a novel promoter, exon 11 (E11) promoter, in the mouse Oprm gene. The E11
promoter is located ~10 kb upstream of the exon 1 (E1) promoter. The E11 promoter controls
the expression of nine splice variants in the mouse Oprm gene. Distinguished from the TATA-less
E1 promoter, the E11 promoter resembles a typical TATA-containing eukaryote class II promoter.
The aim of this study is to further characterize the E11 and E1 promoters in vivo using a transgenic
mouse model.
Results: We constructed a ~20 kb transgenic construct in which a 3.7 kb E11 promoter region
and an 8.9 kb E1 promoter region controlled expression of tau/LacZ and tau/GFP reporters,
respectively. The construct was used to establish a transgenic mouse line. The expression of the
reporter mRNAs, determined by a RT-PCR approach, in the transgenic mice during embryonic
development displayed a temporal pattern similar to that of the endogenous promoters. X-gal
staining for tau/LacZ reporter and GFP imaging for tau/GFP reporter showed that the transgenic
E11 and E1 promoters were widely expressed in various regions of the central nervous system
(CNS). The distribution of tau/GFP reporter in the CNS was similar to that of MOR-1-like
immunoreactivity using an exon 4-specific antibody. However, differential expression of both
promoters was observed in some CNS regions such as the hippocampus and substantia nigra,
suggesting that the E11 and E1 promoters were regulated differently in these regions.
Conclusion: We have generated a transgenic mouse line to study the E11 and E1 promoters in
vivo using tau/LacZ and tau/GFP reporters. The reasonable relevance of the transgenic model was
demonstrated by the temporal and spatial expression of the transgenes as compared to those of
the endogenous transcripts. We believe that these transgenic mice will provide a useful model for
further characterizing the E11 and E1 promoter in vivo under different physiological and
pathological circumstances such as chronic opioid treatment and chronic pain models.
Background
Mu opioid receptors play an essential role in mediating
actions of morphine and most clinical analgesic agents
such as codeine, methadone and oxycodone, as well as
drugs of abuse such as heroin [1,2]. Early pharmacological
studies proposed several mu opioid receptor subtypes:
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mu1, mu2 and morphine-6β-glucuronide (M6G) [3-5].
Molecular cloning of a mu opioid receptor[6], MOR-1,
has provided an invaluable tool to explore multiple mu
opioid receptors at the molecular level. However, only a
single copy of the mu opioid receptor (Oprm) gene has
been identified [7-9]. Alternative pre-mRNA splicing and
multiple promoters of the Oprm gene have been hypothe-
sized as molecular explanations of multiple mu opioid
receptors. Over the past ten years, we have extensively
explored alternative splicing of the Oprm gene, particu-
larly of the mouse Oprm gene. In addition to the rat MOR-
1B and human MOR-1A reported earlier[10,11], we have
identified 25 splice variants from the mouse Oprm gene
[12-16], which are derived from various combinations of
sixteen exons that span over 250 kb. We have also isolated
8 splice variants from the rat Oprm gene and 11 from the
human Oprm gene [17-19]. The functional significance of
these splice variants has been suggested by differences in
their region-specific and cell-specific expressions, agonist-
induced G protein coupling and receptor internaliza-
tion[12,14,17,19-24].
The complexity of the Oprm  gene was further demon-
strated by the identification of multiple promoters. Ini-
tially, promoter activity was mapped to an approximately
1.5 kb region upstream of exon 1 (E1 promoter) in the
mouse, rat and human Oprm genes[7-9,25]. A dual pro-
moter model of the E1 promoter has been proposed, in
which the dominant proximal promoter is approximately
500 bp apart from the distal promoter [26-28]. Within
numerous putative cis-acting elements predicted from the
E1 promoter region by searching transcription factor data-
bases, several cis-acting elements such as a Sp binding
sequence, a 34 bp element, a 26 bp polypyrimidine
sequence, CRE, OCT1, IL-4-responsive element, NF-κap-
paB, SOX, and neuron-restrictive silencer element (NRSE)
in the proximal or distal promoters have been identified
to interact with their trans-acting partners, which posi-
tively or negatively regulate the E1 promoter activity [29-
42]. For example, NRSF (neuron-restrictive silencer fac-
tor) can bind to a 21 bp NRSE element in the proximal
promoter region to suppress the promoter activity [31].
Interestingly, a 10 bp Sp cis-acting element in the proxi-
mal promoter can function either as a negative element
when bound to the M1 and M2 isoforms of Sp3 or as a
positive element by interacting with Sp1 and Sp3[36]. The
poly(C) binding proteins can interact with a 26 bp
polypyrimidine sequence in the proximal promoter to
enhance the transcription of MOR-1 in NMB cells[38,39].
Tumor necrosis factor can induce the mu opioid receptor
gene transcription in several types of immune cells. This
induction has been suggested to be mediated through
induced interaction between NF-κB factor and NF-κB
binding sites located in E1 promoter[41].
Recently, we have identified a new promoter (E11 pro-
moter) in the mouse Oprm gene[43], which was located
~10 kb upstream of the E1 promoter. The E11 promoter
controls the expression of at least nine splice variants in
the mouse Oprm gene. A major transcription start point
was mapped to a guanidine residue, 187 bp upstream
from the putative translation start codon of E11[43]. A
basal core region, a negative region and a positive region
of the E11 promoter, were identified using sequential 5'-
and 3'-deletion constructs in NIE-115 cells, a mouse neu-
roblastoma cell line. The basal core region contains a
TATA box that can specifically bind to a TATA-binding
protein (TBP) in a gel shifting assay[43]. Mutation analy-
sis indicated that the TATA box played an essential role in
the E11 promoter activity, and that a NF-1 site and a
cMyc/Max site near TATA box modulated basal core pro-
moter activity[43].
The E11 promoter differs from the E1 promoter in several
aspects. First, the E11 promoter contains a TATA box that
is absent in the E1 promoter. Second, the E11 promoter
has one major transcription start point (tsp), while the E1
promoter contains multiple tsp. Third, although both pro-
moters have several cis-acting elements such as CAAT box,
AP-1 and NF-κB, the E1 promoter contains several GC-
rich cis-acting elements like Sp1 and AP-2 that are missing
in the E11 promoter. Sp1 regulates a number of TATA-less
promoters. Thus, the E11 promoter appears to be a typical
eukaryote class II promoter associated with RNA polymer-
ase II, while the E1 promoter favors a "housekeeping"
gene mode. Finally, the E1 promoter drives transcription
of 16 variants, while the E11 promoter controls the
expression of 9 other variant transcripts, three of which
can translate into the same MOR-1 protein.
Most promoter studies were performed in vitro using dif-
ferent cell models. Although transgenic technology has
been widely used to characterize opioid receptor func-
tions in vivo, there is little information about their use in
studying transcriptional regulation of the opioid receptor
genes, except for the transgenic studies of the mouse
kappa opioid receptor (Oprk) gene[44]. In the present
studies, we establish a transgenic mouse model using a
single transgenic construct that contains a 3.7 kb E11 pro-
moter region and an 8.9 kb E1 promoter region to drive
expression of two reporters, tau/LacZ and tau/GFP, respec-
tively. This allows characterizing both E11 and E1 pro-
moters in the same transgenic mice with X-gal staining
and GFP imaging.
Results and Discussion
Generation of the transgenic mouse line
In order to study both E11 and E1 promoters in mice, we
made a ~20 kb transgenic construct in a pBR322 vector
(Fig. 1). The construct contained a 3.7 kb region upstreamBMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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of E11 and an 8.9 kb region upstream of E1 that control-
led expression of an IRES/tau/LacZ cassette and an IRES/
tau/GFP cassette, respectively. Our previous studies indi-
cated that the 3.7 kb region contained E11 promoter activ-
ity that was most evident in neuronal cells. A negative
regulatory region, a basal core region containing a TATA
box and a positive regulatory region were identified
within a 600 bp region at the 3'-end of the 3.7 kb frag-
ment. The 8.9 kb fragment included the dual E1 promot-
ers that were characterized by several groups [26-28] and
the regions further upstream.
The internal ribosome entry sequence (IRES) derived from
the encephalomyocarditis virus can directly affect mRNA
cap-independent entry of the translational apparatus in
mammalian cells[45]. IRES can efficiently drive the trans-
lation of downstream tau/LacZ or tau/GFP fusion proteins
in the construct. Tau is a microtubule-associated protein
distributed in the axonal microtubules of neurons[46].
Recently, tau/LacZ and tau/GFP fusion proteins have been
developed as a new generation of axon-targeting reporters
that allow labeling subsets of neurons and their projec-
tions to study neuronal structure and function[47]. Tau/
LacZ and tau/GFP reporters have been used successfully to
reveal the projections of specific subsets of olfactory neu-
rons to their axonal terminal glomeruli in knockin mouse
models[48,49]. Therefore, tau/LacZ and tau/GFP cassettes
were designated in the construct as reporters for E11 and
E1 promoter activities, respectively. We hope that by using
the axon-targeting potential of tau/LacZ and tau/GFP
reporters, we are able to map E11 and E1 promoter activ-
ities not only in their expressing cell bodies but also in
their projections.
Initially, six founder mice were obtained by microinjec-
tion of the construct into the pronucleus of fertilized eggs.
Continuously breeding these founder mice resulted in the
establishment of two transgenic lines (D13 and D10) that
stably expressed the transgene. Both transgenic lines
showed a similar genotyping pattern with a major ~9 kb,
minor ~1.3 kb and weak ~2.8 kb BamHI digested genomic
fragments in Southern blot analysis using a 0.55 kb GFP
probe (Fig. 2), although the D10 line had several addi-
tional weak bands. We also compared the transgene
expression in both lines by using X-gal staining and GFP
imaging. The results showed that both transgenic lines
displayed a similar transgene expression pattern in several
brain regions (see additional file 1: Figure 1 – Compari-
son of tau/LacZ and tau/GFP reporter expression between
two transgenic lines). We used the D13 line for the follow-
ing studies. The transgenic mice were fertile and viable,
with no gross morphological abnormalities.
Schematic of the transgenic construct Figure 1
Schematic of the transgenic construct. Exons and introns are shown by black boxes and horizontal lines, respectively. 
The reporter cassettes are indicated by white boxes. The E11 and E1 promoters are shown by arrows. LoxP sites are shown 
by triangles. The fragments generated by the RT-PCR are indicated by double-head arrows labeled with the predicted sizes. i: 
IRES.
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Expression of endogenous E11 and E1 mRNAs in wild-type 
C57BL/6J mice during ontogeny
Although expression of MOR-1 or E1 promoter during
ontogeny has been extensively studied using RT-PCR, in
situ hybridization and in situ receptor binding[28,50-52],
the expression of the E11-associated variants or E11 pro-
moter during mouse development has not yet been
reported. In order to evaluate whether the transgene in the
transgenic mice has a temporal expression pattern similar
to that of the endogenous E11 promoter, we first exam-
ined expression of the endogenous E11 mRNA during
development. We chose C57BL/6J mice because the trans-
genic mice were generated by backcrossing with C57BL/
6J. Since the E11 promoter controls expression of nine
E11-associated variants in which E11 is the first exon[14],
expression of E11 will be an assessment of the E11 pro-
moter. We examined endogenous E11 mRNA expression
using a relative quantitative RT-PCR approach with prim-
ers derived from E11. The results showed that expression
of the 178 bp E11 transcript in wild-type C57BL/6J mice
started at embryonic day 13.5 (E13.5) (Figs. 3A &3B). The
expression levels of E11 mRNA between E13.5 and E15.5
was quite low (0.025~0.033 amole), and gradually
increased to highest level in adult (0.71 amole).
We also determined expression of a 184 bp exon 1/2 (E1/
2) transcript that was controlled primarily by the E1 pro-
moter using PCRs with the same 1st-strand cDNAs as tem-
plates. As shown in Figs. 3A &3B, the E1/2 mRNA was
detected at E9.5, which was four days earlier than the E11
mRNA (E13.5), suggesting early onset of the E1 promoter
during development. The expression level of the E1/2
transcript at E9.5 and E10.5 was low (0.24~0.31 amole),
slowly increased from E11.5 to P0 (1.15~5.30 amole),
and reached to highest level in adult (13.48 amole). Our
results are similar to those in the literature. Zhu et al.
reported the detection of MOR-1 mRNA at E10.5 using an
in situ hybridization approach with a [33P]-labeled RNA
probe derived from exon 1[51], which was one day later
than our result. Using a combined RT-PCR/Southern blot
approach, Ko et al. detected the expression of both the
exon 1/2 and the exon 1 transcripts controlled by the dual
exon 1 promoters as early as E8.5[28], which was one day
earlier than our result. These differences are likely the
result of differences in the sensitivities of the assay meth-
ods or differences among the strains. However, all these
studies observe an appearance of E1 activity at least 3 days
prior to E11 activity.
The later onset of the E11 promoter activity during mouse
embryonic development suggested differential regulation
of the E11 and E1 promoters and raised questions regard-
ing their functional roles in development. Further investi-
gation and identification of the cis-acting elements and
trans-acting factors involved in the E1 and E11 promoters
will help illuminate the mechanisms behind such differ-
ential regulation.
The results also indicated higher levels of E1/2 mRNA
than E11 mRNA during development and in the adult. For
example, the E1/2 transcripts detected from E16.5 to
E18.5 were 10 – 24-fold higher than the E11 transcripts
(Figs. 3A &3B). In adult brain, there was an >18-fold dif-
ference between the E1/2 and E11 transcripts (Figs. 3A
&3B), which is consistent with our previous observations
in the adult brain tissues[14]. Designing specific primers
for amplifying E1 promoter-driven transcripts is difficult
since some of the E11-associated variants also contain an
exon 1 region that includes part of the proximal promoter
sequence. Therefore, the E1/2 primers also amplifies sev-
eral E11-associated variants that contain the exons 1–2
sequence. However, since the expression level of the E11-
associated transcripts was much lower than that of E1-
associated transcripts, we considered the PCR products
generated from E1/2 primers reasonable indications of E1
Southern blot analysis Figure 2
Southern blot analysis. Southern blot analysis was per-
formed as described in the Methods section. Briefly, 5 µg 
genomic DNA from two transgenic lines, D13 and D10, was 
digested with BamHI, separated on 0.8% agarose gel and 
transferred onto a GenePlus membrane. The membrane 
hybridized with the GFP probe was exposed to the Kodak 
BioMax MS film.BMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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Expression of the endogenous E11 and E1 mRNAs in wide-type C57BL/6J mice during ontogeny Figure 3
Expression of the endogenous E11 and E1 mRNAs in wide-type C57BL/6J mice during ontogeny. A. RT-PCR: The 
temporal expression of a 184 bp exons 1/2 (Exon 1/2) and a 178 bp exon 11 (Exon 11)transcripts during ontogeny of C57BL/
6J mice was determined by a relative quantitative RT-PCR approach as described in the Methods section. RNA input was esti-
mated by a parallel PCR with a pair of G3PDH primers. Agarose gel stained with ethidium bromide was photographed with 
FluorChem 8000 system. PCR cycles and extension time at 72°C: for Exon 1/2 primer set, 35 cycles and 20 sec; for Exon 11 
primer set, 45 cycles and 20 sec; and for G3PDH primer set, 25 cycles and 2 min. B. Relative quantification: Relative band inten-
sities from the gel were quantified with AlphaEase FC software, and converted to amole concentration based upon the linear 
regression equations from the linear phase of each saturation curve (see Fig. 8) using Prism 4.0. The concentration was normal-
ized with the G3PDH concentration. Right Y axis represents the concentration of Exon 11 cDNA, and left Y axis, the concen-
tration of Exon 1/2 cDNA. Bars represent the mean ± S.E. of the concentration from three independent experiments.BMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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promoter activity. However, functional significance can-
not be assigned only upon the overall abundance of a
transcript. Regional and cell-specific expression should
also be taken into account. In previous studies, we have
shown regional-specific or cell-specific expression of
some variants at both mRNA and protein lev-
els[12,14,20,21]. For example, expression of MOR-1C
mRNA was quite low when using the RNA from the total
brain[12], but MOR-1C protein was highly expressed in
certain regions such as the Lateral septum and Median
eminence, when compared to the expression of MOR-1
protein[20]. It will be interesting to further explore the
temporal and spatial expression patterns of these E11
mRNAs during development and in adult CNS, using an
in situ hybridization approach.
Expression of the transgene mRNAs in transgenic mice 
during ontogeny
In order to compare directly the endogenous E11 and E1
promoters with the transgenes, we examined the expres-
sion of endogenous E11 and E1/2 mRNA during develop-
ment in the transgenic line using the same RT-PCR
approach. Since the 3'-end of exon 11 coding sequence
was not included in the transgenic construct, the E11
primer used for the endogenous gene would not amplify
the transgene. As shown in Figs. 4A &4B, we observed the
same expression profiles of E11 and E1/2 mRNA in the
transgenic mice as seen in the wild-type C57BL/6J mice.
The appearance of E11 and E1/2 mRNA was at E13.5 and
E9.5, respectively. The expression level of E11 transcript
between E13.5 and E15.5 was also low (0.06~0.10
amole), and gradually increased to the highest level in
adult brain (1.15 amole).
We then examined temporal expression of the transgenes
using the same RNAs in the RT-PCR with primers specifi-
cally designed for the transgenes. The E11/LacZ mRNA,
which is controlled by the 3.7 kb E11 promoter in the
transgenic construct, was detected as early as E11.5, which
was two days earlier than the onset of endogenous E11
mRNA (Fig. 4). The expression level of the E11/tau tran-
script at E11.5 was quite low (0.04 amole), and slowly
increased to higher levels in adult brains (2.31 amole).
The E1/tau mRNA, which was transcribed through the 8.9
kb E1 promoter in the transgenic construct, was detected
at E7.5, which was also two days earlier than the endog-
enous E1/2 mRNA (E9.5). The expression level of E1/tau
transcript between E11.5 and E13.5 was low (0.98~1.36
amole), and gradually increased to higher levels in adult
brain (13.19 amole). The expression level of both E11/tau
and E1/tau transcripts were comparable to those of the
endogenous transcripts (Fig. 4B). These results confirm
the same relative temporal appearance of the E11 and E1
promoters in the transgenic construct, with the E1/tau
mRNA appearing 4 days prior to the E11, similar to that
of the endogenous promoters. The earlier appearance of
the transgene mRNA may be due to a variety of factors.
Distal control elements may be lacking in the transgenic
construct, or adjacent elements of the integration site may
be influencing expression. Nevertheless, the ability of the
transgene to maintain the four day difference in expres-
sion between the two promoters implies that the trans-
genic mice provide a relevant model to study the E11 and
E1 promoters in vivo.
Distribution of tau/LacZ and tau/GFP reporters in the 
transgenic mouse central nervous system
We next examined brain distributions in the transgenic
mice of the two reporter proteins, tau/LacZ and tau/GFP,
which were controlled by the transgenic E11 and E1 pro-
moters, respectively, using X-gal staining and GFP imag-
ing. X-gal staining for tau/LacZ reporter activity, which is
under the control of the E11 promoter, was examined in
brain sections after perfusion, whereas GFP imaging for
the tau/GFP reporter used fresh-frozen sections. Sections
with similar regions were selected for comparison.
We observed that both reporter activities were widely dis-
tributed in a number of brain regions, such as the piriform
cortex, olfactory bulb, striatum, hippocampal formation,
thalamus, substantia nigra, hypothalamus, brainstem,
purkinje cells and spinal cord (Figs. 5 &6 and Table 1).
The distribution pattern of the tau/GFP reporter was gen-
erally comparable to that obtained from in situ hybridiza-
tion studies using probes derived from MOR-1 (exons 1–
4) sequences [53-55] and to immunohistochemical stud-
ies using polyclonal antibodies generated against the last
12 or 15 amino acids of C-terminus of MOR-1 in rat
[20,56,57]. However, these published data were mainly
derived from rat brain and spinal cord sections. To directly
compare tau/GFP reporter with MOR-1-LI, we examined
MOR-1-LI in brain and spinal cord of the transgenic and
wide-type C57BL/6J mice with a polyclonal antibody
against the last 15 amino acids of MOR-1. Since the 12 of
15 amino acids are derived from exon 4, we also refer this
antibody immunoreactivity to exon 4-like immunoreac-
tivity (E4-LI). We observed similar E4-LI distributions in
both the transgenic and wide-type C57BL/6J mice (data
not shown), suggesting that the transgene had little effect
on E4-LI distribution. As shown in Fig. 7 and Table 1, E4-
LI in transgenic mice also was similar to studies in the rat
[20,56,57]. For example, the hippocampal formation and
the superficial laminae of the spinal cord were intensely
labeled in both mice and rat.
The distribution of tau/GFP reporter mimicked that of E4-
LI in transgenic mice (Figs. 5, 6, 7 and Table 1), including
the olfactory bulb, piriform cortex, thalamus, cerebellum
and spinal cord. Since E4-LI represented the MOR-1
expression mainly controlled by the E1 promoter, theseBMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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Expression of the endogenous E11 and E1 and the transgene mRNAs in the transgenic mice during ontogeny Figure 4
Expression of the endogenous E11 and E1 and thetransgene mRNAs in the transgenic mice during ontogeny. 
A. RT-PCR:The temporal expression of a 184 bp exons 1/2 (Exon 1/2) and a 178 bp exon 11 (Exon 11) transcripts during 
ontogeny of transgenic mice was determined by the same relative quantitative RT-PCR approach used in C57BL/6J mice. A 
0.95 kb Exon 1/tau transcript and a 0.9 kb Exon 11/tau transcript were determined by a similar RT-PCR approach using the 
same first-strand cDNAs as templates, as described in the Methods section. RNA input was estimated by a parallel PCR with a 
pair of G3PDH primers. Agarose gel stained with ethidium bromide was photographed with FluorChem 8000 system. PCR 
cycles and extension time at 72°C: for Exon 1/2 primer set, 35 cycles and 20 sec; for Exon 11 primer set, 45 cycles and 20 sec; 
for Exon 1/tau primer set, 35 cycles and 2 min; for Exon 11/tau primer set, 45 cycles and 2 min, and for G3PDH primer set, 25 
cycles and 2 min. B. Relative quantification: Relative band intensities from ethidium bromide-stained gel were quantified with 
AlphaEase FC software, and converted to amole concentration based upon the linear regression equations from the linear 
phase of each saturation curve (see Fig. 8) using Prism 4.0. The concentration was normalized with the G3PDH concentration. 
Right Y axis represents the concentration of Exon 11 and Exon11/tau cDNAs, and left Y axis, the concentration of Exon 1/2 
and Exon 1/tau cDNAs. Bars represent the mean ± S.E. of the concentration from three independent experiments.BMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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Distribution of the tau/LacZ and tau/GFP fusion proteins in the transgenic mouse brain Figure 5
Distribution of the tau/LacZ and tau/GFP fusion proteins in the transgenic mouse brain. The left two columns 
shows X-gal staining and the right two columns, GFP imaging. The second column B, F, J, N and R is the higher power of boxes 
indicated in the first column A, E, I, M and Q, respectively. The last column D, H, L, P and T is the higher power of boxes 
shown in the third column C, G, K, O and S, respectively. GL, glomerular layer of the olfactory bulb; LPtA, lateral parietal asso-
ciation cortex; SNC, substantia nigra, compact; SNR, substantia nigra, reticular; CA1, field CA1 of hippocampus; CA2, field 
CA2 of hippocampus; CA3, field CA3 of hippocampus; Med, medial cerebellar nucleus; Pl, purkinje cell layer. Scale bar = 250 
µm (A, C, E, G, I, K, M, O, Q and S) or 50 µm (B, D, F, H, J, L, N, P, R and T).BMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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Distribution of the tau/LacZ and tau/GFP fusion proteins in the transgenic mouse spinal cord Figure 6
Distribution of the tau/LacZ and tau/GFP fusion proteins in the transgenic mouse spinal cord. A & B are X-gal 
staining, and C & D, GFP imaging of lumbar sections. B and D are the higher power of boxes shown in A and C, respectively. I 
– VI, laminae layers. Scale bar = 250 µm (A and C) or 50 µm (B and D).BMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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results suggested that the tau/GFP reporter reasonably
resembled the endogenous E1 promoter expression. How-
ever, there were some subtle differences. For example, tau/
GFP reporter was primarily observed in the CA3 region of
the hippocampus, while the E4-LI was distributed
throughout the CA1, CA2 and CA3 regions. In the spinal
cord, both tau/GFP reporter and E4-LI were heavily
detected in the superficial laminae, but the tau/GFP
reporter seemed to label more large neurons in the deep
laminae. Different targets designated by these two meth-
ods may explain these disparities. The tau/GFP reporter
was driven by the transgenic E1 promoter, but E4-LI only
detected variants expressing the exon 4 sequences. There
are 14 additional variants under the control of the E1 pro-
moter that do not contain exon 4. Therefore, the labeling
in the deep laminae of the spinal cord by the tau/GFP
reporter may represent expression of those E1 promoter-
driven variants other than MOR-1 itself. On the other
hand, there are three E11 promoter-driven transcripts
(mMOR-1 H, mMOR-1I and mMOR-1J) that contain
exon 4 and that can generate the same identical protein as
MOR-1. Thus, more labeling by the exon 4 antibody and
less labeling by tau/GFP reporter in the CA1 and CA2
regions of the hippocampus may indicate that E4-LI seen
in the CA1 and CA2 regions reveal transcripts driven by
the E11 promoter. This possibility is supported by the
Table 1: Distribution of E11 and E1 promoter activities in the transgenic CNS
Structure tau/LacZ (E11 promoter) E11-LI tau/GFP (E1 promoter) E4-LI
Cerebral cortex
Piriform cortex +++ - +++ ++
Lateral parietal association cortex + - ++ +
Primary motor cortex + - + +
Olfactory system
Olfactory bulb ++ - + +
Olfactory tubercule + ++ +/- +
Striatum + + + ++
Nucleus accumbens + + + ++
Globus pallidus + + + +
Ammon's horn
CA1 ++ - +/- +
CA2 ++ - +/- +
CA3 +++ - +++ ++
Pyramidal cell layer + - + +
Polymorph layer dentate gyrus ++ - + +
Subthalamic nucleus +/- - +++ ++
Zona incerta + - + -
Thalamus
Laterodorsal thalamic nucleus ++ - +/- +
Lateral posterio thalamic nucleus ++ - +/- +
Ventral posteromedial thalamic nucleus + - ++ +/-
Ventral posterolateral thalamic nucleus + - ++ +/-
Hypothalamus + - + +
Substantia nigra, reticular ++ ++ +/- +/-
Substantia nigra, compact +++ - ++ +
Locus coeruleus + - + ++
Cerebellum
Purkinje cell +++ - +++ +++
Medial cerebellar nucleus ++ - ++ ++
Brainstem ++ - ++ ++
Spinal cord
Laminae I-II + - +++ +++
Laminae III-IV + - ++ +
Laminae V-VI + - ++ +
Laminae VII-VIII + - ++ +
Laminae IX + - ++ +
E11 promoter activity indicated by X-gal staining of tau/LacZ fusion protein, E1 promoter activity indicated by GFP imaging of tau/GFP fusion 
protein and exon 4-like immunoreactivity (E4-LI) shown by immunostaining with an E4 antibody in the selected areas of the transgenic mice are 
presented. The intensity of X-gal staining, green fluorescent protein signal and Alex568 fluorescence of MOR-1-LI was visually estimated as high 
(+++), moderate (++), low (+), very low (+/-), and negative (-). Exon 11-like immunoreactivity (E11-LI) is from the literature[58].BMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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expression of the tau/LacZ reporter driven by the trans-
genic E11 promoter in the CA1 and CA2 regions (Fig. 5M–
N). However, this possibility remains speculative.
We also observed the expression of tau/LacZ reporter in
various CNS regions (Figs 5 &6 and Table 1). Previously,
we examined the distribution of exon 11-like immunore-
activity (E11-LI) in the mouse CNS with a polyclonal anti-
body generated against a 22-residue peptide from exon 11
[58]. E11-LI was observed primarily in the olfactory tuber-
cle, striatum, globus pallidus and substantia nigra. Tau/
LacZ reporter was also expressed in these regions. How-
ever, the E11-LI had a very limited distribution in the CNS
in contrast to the wide distribution of tau/LacZ reporter
(Table 1). There are several potential explanations. First,
the tau/LacZ reporter measures the activity of the trans-
genic E11 promoter, and resembles the expression of all
E11-associated variants. Since several E11-associated tran-
scripts (MOR-1 H, MOR-1I and MOR-1J) can produce the
same MOR-1 protein lacking the exon 11 epitope, the
exon 11 antibody was incapable of detecting these pro-
teins. Therefore, the tau/LacZ reporter reflects a broader
range of variants than those identified with only the exon
11 antibody. Secondly, mismatches between the distribu-
tions of mRNA and protein within the brain are not
uncommon. Mismatches have been observed for mu opi-
oid receptors when comparing in situ hybridization,
immunoreactivity and receptor binding between receptor
mRNA and protein expression [59,60]. We also observed
some mismatches between the mRNA and protein distri-
bution of the E11-associated variants[14,58]. One possi-
ble explanation is that receptor proteins may be
synthesized in cell bodies from one region and then trans-
ported to their terminals located in the other region,
whereas mRNA is primarily localized in the cell body. The
exon 11 antibody only detected the exon 11-associated
proteins. If the exon 11 expressing proteins are trans-
ported away from the cell body, the antibody may only
label the projection areas and not the cell bodies them-
selves. Thirdly, these differences may be dependent upon
different assay sensitivities. For example, X-gal staining
might be more sensitive than the exon 11 immunohisto-
chemistry. Although tau/LacZ reporter was anticipated to
resemble E11 promoter activity, the complete distribution
patterns of the endogenous E11 promoter activity at both
mRNA and protein levels have not been determined.
However, a tau/LacZ reporter in our exon11 knockin/
knockout mice, in which the exon 11 coding and adjacent
Distribution of E4-LI in the transgenic mouse CNS Figure 7
Distribution of E4-LI in the transgenic mouse CNS. Brain and spinal cord sections were labeled with the exon 4-specific 
antibody, as described in the Methods section. B, D, F and H are the higher power of boxes shown in A, C, E and G, respec-
tively. GL, glomerular layer of the olfactory bulb; CA1, field CA1 of hippocampus; CA2, field CA2 of hippocampus; CA3, field 
CA3 of hippocampus; Med, medial cerebellar nucleus; Pl, purkinje cell layer. I-VI, laminae layers of lumber section. Scale bar = 
250 µm (A, C, E, and G) or 50 µm (B, D, F and H).BMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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intron regions were replaced by an IRES/tau/LacZ/neo cas-
sette through homologous recombination, displayed a
distribution pattern very similar to that of the transgenic
mice (Xu, Rossi, Matulonis, Pasternak and Pan, unpub-
lished data), further supporting the relevance of the cur-
rent model.
Although both tau/LacZ and tau/GFP reporters were
widely distributed in various CNS regions such as the pir-
iform cortex, olfactory bulb, striatum, hippocampal for-
mation, thalamus, substantia nigra, hypothalamus,
brainstem, purkinje cells and spinal cord, the distribution
patterns of the two reporters differed in certain brain
regions. For example, in the lateral parietal association
cortex, tau/GFP reporter was expressed over multiple lay-
ers, while tau/LacZ reporter was distributed in the middle
layers only (Fig. 5E–H). In the hippocampal formation,
tau/LacZ activity was observed in the pyramidal cell layer
throughout the CA1, CA2 and CA3 regions, but tau/GFP
activity was limited to the CA3 region (Fig. 5M–P). In the
pars reticulate of the substantia nigra, the tau/LacZ
reporter appeared to be expressed in more neurons than
did the tau/GFP reporter (Fig. 5I–L). These differential dis-
tributions provided in vivo evidence that the E11 and E1
promoters were differentially regulated in these CNS
regions.
Interestingly, both tau/LacZ and tau/GFP expression were
quite prominent in Purkinje cells and in the medial cere-
bellar nucleus, suggesting potential roles in motor actions
(Fig. 5Q–T). Although a number of studies using in situ
hybridization and immunohistochemistry failed to detect
MOR-1 expression in the cerebellum [20,56,57], others
observed MOR-1 expression at both the mRNA and pro-
tein levels [12,13,55,61-63]. For example, Mrkusich et al.
demonstrated abundant expression of both MOR-1
mRNA by fluorescent in situ hybridization and MOR-1
protein by immunostaining with an exon 4-specific anti-
body in the rat cerebellum, particularly within Purkinje
cells and the deep cerebellar nuclei[61]. Using an in situ
hybridization approach with a 35S-labeled 777 bp MOR-1
probe, Kaufman et al. showed moderate labeling in the
medial and interposed deep nuclei in the mouse cerebel-
lum[55]. MOR-1C, MOR-1F and MOR-1 mRNAs were
also detected in the mouse cerebellum by a RT-PCR
approach [12,13]. Moreover, mMOR-1B4-like immunore-
activity was densely distributed in Purkinje cells and the
deep cerebellar nuclei[62]. The expression of tau/LacZ
and tau/GFP reporters in Purkinje cells and medial cere-
bellar nucleus of our transgenic mice supported these pos-
itive findings.
In the spinal cord, both reporters were mostly distributed
in the lumbar and sacral segments as compared with the
cervical and thoracic segments. In the lumber segments,
the expression of tau/GFP reporter appeared higher than
that of tau/LacZ reporter throughout all laminae (Fig. 6).
Tau/GFP reporter was intensively expressed in the superfi-
cial laminae, and also scattered in a number of motor neu-
rons in the deeper laminae (Fig. 6C–D). Tau/LacZ reporter
was also mainly distributed in laminae I-II, but had less
intense labeling than tau/GFP reporter. Tau/LacZ was also
observed in the larger motor neurons in the deeper lami-
nae (Fig. 6A–B).
Conclusion
We have established a transgenic mouse line using a ~20
kb transgenic construct in which the 3.7 kb E11 promoter
region and the 8.9 kb E1 promoter region control expres-
sion of the tau/LacZ and tau/GFP reporters, respectively.
This transgenic model permits studying the E11 and E1
promoters of the mouse Oprm gene in vivo. Temporal and
spatial expressions of these reporters were similar to that
of the endogenous promoters, suggesting the reasonable
relevance of this transgenic model. Although the E11 tran-
script was expressed at lower levels, as determined by RT-
PCR, differential expression of E11 and E1 promoters dur-
ing embryonic development and in various CNS regions
provides another mechanism for transcriptional regula-
tion of the Oprm gene. We anticipate that these transgenic
mice will also offer a useful in vivo model to study the E11
and E1 promoters under different physiological and path-
ological conditions such as chronic opioid treatment and
chronic pain models.
Methods
Transgenic construct
A 1.1 kb tau fragment was amplified by PCR with a sense
primer containing a NcoI site (5'-GAA CCA CCA TGG
CTG AGC CCC GCC AGG AGT TCG ACG-3') and an anti-
sense primer containing a BamHI site (5'-GAT GGG ATC
CCC GGA CAC GAT CTC CGC CCC GTG GTC GGT CTT
GG-3') using the first-cDNA synthesized from Bovine
brain mRNA (ClonTech) as template. A 3.1 kb LacZ frag-
ment was generated by PCR with a sense primer contain-
ing a BamHI site (5'-CGG GGA TCC CGT CGT TTT ACA
ACG TCG TG-3') and an antisense primer containing a
loxP sequence with a FseI and a AflII site (5'-GAT TGC CTT
AAG GGC CGG CCA TAA CTT CGT ATA GCA TAC ATT
ATA CGA AGT TAT CCC CCC TGC CCG GTT ATT ATT ATT
TTT GAC ACC-3') using pMC1871 vector (Pharmacia) as
template. A 0.7 kb GFP fragment was produced by PCR
with a sense primer containing a BamHI site (5'-GAC
GGG GAT CCC GTG AGC AAG GGC GAG GAG CTG TTC-
3') and an antisense primer containing a loxP sequence
with a PacI and a AflII site (5'-GAT TGC CTT AAG TTA ATT
AAG ATA ACT TCG TAT AGCATA CAT TAT ACG AAG TTA
TAG AGT CGC GGC CGC TTT ACT TGT AC-3') using
pEGFP-1 vector (ClonTech) as template. In order to con-
struct IRES/tau/LacZ and IRES/tau/GFP cassettes, the 0.6BMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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kb EcoRI/NcoI IRES fragment cut from a IRES/tau/LacZ/
LTNL cassette, a kind gift from Dr. Peter Mombaerts, the
Rockefeller University, who has productively used it to
study the olfactory system[48], the 1.1 kb NcoI/BamHI
tau fragment and the 3.1 kb BamHI/AflII LacZ or the 0.7
kb BamHI/AflII GFP fragment were sequentially sub-
cloned into the EcoRI/AflII sites pcDNA3.1 vector con-
taining an AscI site in the polylinker, to construct IRES/
tau/LacZ-pcDNA3 and IRES/tau/GFP-pcDNA3 vectors,
respectively, in which the tau was in frame with LacZ or
GFP to make tau/LacZ or tau/GFP fusion protein. Then a
3.7 kb XbaI/XhoI fragment containing the exon 11 and its
upstream promoter region amplified by PCR with a sense
primer containing a XbaI site (5'-GAC TCT AGA GCA TTG
TGG TAT GCC ATT ACT ATC CAT TTA C-3') and an anti-
sense primer containing a XhoI site (5'-GAC CTC GAG
GAA AGC TTC CAT CAT CGG CCC AGA TCC-3') was sub-
cloned into the XbaI/XhoI sites of IRES/tau/LacZ-pcDNA3
vector to construct E11P/IRES/tau/LacZ-pcDNA3 vector.
For subsequent cloning, the IRES/tau/GFP cassette
digested with NheI/AflII from IRES/tau/GFP-pcDNA3 was
subcloned into NheI/AflII sites of pBR322 vector contain-
ing an unique polyliner (PacI-AscI-FseI-NheI-AflII) to
construct IRES/tau/GFP-pBR322 vector. A 8.9 kb FseI/
NheI genomic fragment containing exons 12 and 1 and
exon 1 promoter region generated by PCR from a mouse
genomic BAC clone[14] with a sense primer including a
FseI site (5'-GAC CAC TTA GGC CGG CCA AAA GCT CAG
ACA GAG AGA TGG AAA TCA AGA GGG GAA GAG-3')
and an antisense primer including a NheI site (5'-GAC
ACT GCT AGC TGC TGT CCA TGG TTC TGA ATG CTT
GCT GCG GAC TCG GTA GGC-3') was then subcloned
into the FseI/NheI sites of IRES/tau/GFP-pBR322 vector to
construct E1P/IRES/tau/GFP-pBR322 vector. Finally, the
E11P/IRESP/tau/LacZ cassette digested with AscI/FseI
from the E11P/IRES/tau/LacZ-pcDNA3 vector was sub-
cloned into the AscI/FseI sites of E1P/IRES/tau/GFP-
pBR322 vector to make the final construct with a ~20 kb
insert in pBR322 vector (Fig. 1). Two loxP sites were
included in the construct, one located at downstream of
the tau/LacZ cassette and the other at downstream of the
tau/GFP cassette, which allows Cre-mediated recombina-
tion to remove E1 promoter and tau/GFP cassette. All PCR
products and cloning joints were confirmed by DNA
sequencing with appropriated primers.
Generation of transgenic mice
DNA microinjection and embryonic manipulations were
performed in Transgenic Core Facility of MSKCC using
standard procedures[64]. Briefly, the linearilized vector
with AscI was injected into pronuclei in one-cell eggs that
were isolated from superovulated C57BL/6J females
mated with CBA/Ca males (B6CBA/Ca F1). About 20–30
injected ova were transplanted into the oviduct of a pseu-
dopregnant B6CBA/Ca F1 recipient that carries the eggs to
term. Genotyping was performed by Southern blot analy-
sis of genomic DNA isolated from offspring tails using a
0.55 kb GFP fragment as probe. The integrity of the trans-
gene in the transgenic lines was confirmed by PCRs with
appropriate primers. The transgenic lines with stable
transgene transmission were established by continuously
backcrossing the founder with C57BL/6J mice.
Southern blot analysis
Genomic DNA was isolated from mouse tails using a
DNeasy kit (Qiagen) by following the manufacture proto-
col. 5 µg genomic DNA was digested with BamHI, sepa-
rated on 0.8% agarose gel, and transferred onto GenPlus
membrane (NEB). The membrane was hybridized with a
32P-labeled 0.55 kb GFP probe generated by PCR with
appropriate primers. After washing, the membrane was
exposed to Kodak BioMax MS film.
Tissue preparation and RNA isolation
All animal studies were conducted in accordance with the
Guide for the care and use of laboratory animals and the
Animal Welfare Act, and reviewed and approved by the
IACUC. Mouse embryos were collected at various devel-
opmental stages between days 6.5 and 18.5 (E6.5–E18.5)
from wild-type C57BL/6J and transgenic females based
upon the standard procedures as described[64]. Morning
on the day of detecting a vaginal plug was designated as
day 0.5. The day of birth was designated as P0. All
embryos were dissected free of maternal tissue. 20 – 40
embryos from E6.5 to E9.5, 10 – 15 embryos from E10.5
to E12.5, 5 – 8 embryos from E13.5 to E15.5, and 2 – 3
embryos from E16.5 to P0 were collected for RNA extrac-
tion. The embryos from E6.5 to E15.5 were pooled, while
individual embryos from the rest stages were used. Whole
embryo tissue from E6.5 to E10.5 and brain from E11.5 –
E18.5 embryos, P0 and adult mice were used for extracting
total RNA using the guanidinum thiocyanate phenol-
chloroform extraction method[65].
Reverse-transcription-polymerase chain reaction (RT-
PCR)
6 µg of total RNA was treated with DNAse I using the
Turbo DNAse-free reagents (Ambion) to remove poten-
tially contaminated genomic DNA, and reverse-tran-
scribed with random hexamers and Superscript II reverse
transcriptase (Invitrogen) as previously described[12,14].
The RT product was treated with RNase H to remove RNA
complementary to the first-strand cDNA. The first-strand
cDNA synthesized from 0.3 µg RNA was then used as a
template in PCRs to amplify a 178 bp endogenous E11
fragment with a sense primer (5'-GTC CTT GAG AAT GGA
GAG GAT CAG CAA AGC-3') and an antisense primer (5'-
CTG AGG TAA CTC TTC CCC TCT TGA TTT C-3'), a 184
bp endogenous exon 1/2 fragment with a sense primer
(5'-GCC CTC TAT TCT ATC GTG TGT GTA GTG G-3') andBMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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an antisense primer (5'-CCA CGT TCC CAT CAG GTA GTT
AAC AC-3'), a 0.9 kb E11/tau fragment with a sense
primer from E11 (5'-GAT CTG GGC CGA TGA GGA AGC
TTT CTC-3') and an antisense primer from tau (5'-GTC
GGA GTG CTC TTA GCA TCA GAG GTT TCA G-3') and a
0.95 kb E1/au fragment with a sense primer from E1 (5'-
GCT TGT CCT TGT AAG AAA CTG ACG GAG CCT AG-3)
and antisense primer from tau (5'-GTC GGA GTG CTC
TTA GCA TCA GAG GTT TCA G-3'). RNA loading was esti-
mated by a parallel PCR with a pair of glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) primers (ClonTech).
A negative control template obtained from a RT reaction
without adding Superscript II was also used in the PCRs
with the same pairs of primers. PCR reactions were carried
out using Platinum Taq DNA polymerase (Invitrogen) for
25 – 45 cycles after 2 min at 94°C, each cycle consisting
of a 20 sec denaturing step at 94°C, a 20 sec annealing
step at 65°C and a 20 – 120 sec extension at 72°C. The
PCR products were analyzed in the same 2% agarose gel,
stained with ethidium bromide and photographed with
FluorChem 8000 Image system (Alpha Innotech). The rel-
ative band intensities from the gel were quantified with
AlphaEase FC software. The amplified fragments were
confirmed by sequencing. In order to quantify the
amount of transcripts from different target with a wide
range of abundance, various PCR cycle numbers and
extension times were adjusted to amplify cDNA at linear
phase. For lower abundant E11 and E11-tau transcripts,
we used 45 cycles/20 sec extension and 45 cycle/120 sec
extension, respectively. For medium abundant E1/2 and
E1-tau transcripts, we amplified for 35 cycles/20 sec and
35 cycles/120 sec, respectively. For higher abundant
G3PDH transcript, we only used 25 cycles/120 sec exten-
sion. We also obtained the same results from PCRs with
amplification for 50 cycles except that the products
seemed saturated (data not shown). To quantify the tran-
scripts more accurately, we first established the saturation
curve with the known concentration of plasmid contain-
ing the target sequences with each pair of primers. The
plasmid concentration was ranged from 0.001, 0.01, 0.1,
1, 10, 100, 1000 and 10,000 atto mole (amole). As shown
in Fig. 8, the linear phase of amplification for E11 and
E11/tau sequences, E1 and E1/tau sequence, and G3PDH
sequence was 0.01~10 amole, 0.1~100 amole, and
1~10,000 amole, respectively. The PCR products at higher
template concentrations under certain PCR cycle condi-
tions tended to be saturated. The linear regression equa-
tion for each curve was calculated from the linear phase of
amplification using Prism 4.0. The sample concentration
was calculated based upon the linear regression equation,
and normalized with the G3PDH concentration. As
expected, most amplification for various samples and tar-
gets were maintained in the linear phase of amplification
(Fig. 8).
X-gal staining and GFP imaging
Mice were anesthetized with Ketamine-xylazine and tran-
scardially perfused with 4% paraformaldehyde in PBS.
Brain and spinal cord tissues were dissected, post-fixed
with 4% paraformaldehyde in PBS for 2 hrs, incubated
with 25% sucrose in PBS at 4°C until tissue sank to bot-
tom, and frozen in Tissue-Tek OCT (Miles, Elkhart, IN).
10 micrometer frozen sections were cut on a Leica Cryom-
icrotome and used for X-gal staining as follows. The sec-
tions were washed with PBS and incubated with X-gal
staining solution containing 2 mM MgCl2, 10 mM potas-
sium-ferricyanide, 10 mM potassium-ferrocyanide and 1
mg/ml X-gal in PBS for 18 hrs at 37°C. After washing with
PBS, the sections were counterstained with Nuclear Fast
Red (Vector Lab), dehydrated and mounted with Per-
mount (Fisher). 10 micrometer frozen sections cut from
fresh frozen tissues were directly used for GFP imaging. All
sections were examined and photographed with a Zeiss
PCR saturation studies Figure 8
PCR saturation studies. Saturation curve for each set of 
primers with different PCR cycles was established as 
described in the Methods section. In brief, PCRs with the 
indicated primer sets and cycle numbers were performed by 
using templates from a series of dilution of the known con-
centration of plasmids containing the target sequences. The 
plasmid concentration was ranged from 0.001, 0.01, 0.1, 1, 
10, 100, 1000 and 10,000 amole. Relative band intensities 
from the ethidium bromide-stained gel were quantified with 
AlphaEase FC software. The linear phase of amplification for 
Exon 11 and Exon 11/tau targets (0.01 – 10 amole), Exon 1 
and Exon 1/tau targets (0.1 – 100 amole), and G3PDH target 
(1~10,000 amole) was used to establish the linear regression 
equation using Prism 4.0. The sample concentration was cal-
culated from the linear regression equation. The curves rep-
resented from three to six independent experiments. Each 
individual spot represents a single sample from the indicated 
primer set. Only part of the samples is displayed.BMC Molecular Biology 2006, 7:41 http://www.biomedcentral.com/1471-2199/7/41
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Axioplan 2 Imaging microscopes with ApoTome™ or a
Zeiss Axiovert 200 M with a MetaMorph Imaging System.
Immunohistochemistry
10 micrometer frozen sections from the perfused tissues
prepared from the same procedure for X-gal staining were
used for immunostaining. After blocking in a blocking
solution containing 5% normal goat serum (NGS) in PBS
for 1 hr at room temperature, the sections were incubated
with a rabbit polyclonal antibody generated against the
last 15 amino acids of MOR-1 (Neuromics, Minneapolis,
MN) in PBS containing 3% NGS (1:50 dilution) overnight
at 4°C, washed three times with PBS, blocked in the above
blocking solution for 30 min at room temperature, and
then incubated with an Alexa Fluor 568 conjugated goat
anti-rabbit IgG (Molecular Probe) (1:500 dilution). After
washing three times with PBS, the sections were cover-
slipped with Vectashield mounting medium (Vector Lab-
oratories) and examined and photographed with a Zeiss
Axioplan 2 Imaging microscopes with ApoTome™.
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